Ravi S. Narayan
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype.
Journal: Molecular cancer therapeutics
Published: December 07, 2023
Preclinical evaluation of binimetinib (MEK162) delivered via polymeric nanocarriers in combination with radiation and temozolomide in glioma.
Journal: Journal of neuro-oncology
Published: October 30, 2019
A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities.
Journal: Nature communications
Published: April 12, 2019
WINDOW consortium: A path towards increased therapy efficacy against glioblastoma.
Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
Published: July 17, 2018
Identification of MEK162 as a Radiosensitizer for the Treatment of Glioblastoma.
Journal: Molecular cancer therapeutics
Published: May 24, 2017
The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures.
Journal: BMC cancer
Published: October 13, 2016
Role of Akt signaling in resistance to DNA-targeted therapy.
Journal: World journal of clinical oncology
Published: March 23, 2016
NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor.
Journal: Oncotarget
Published: January 10, 2015
Targeting the Akt-pathway to improve radiosensitivity in glioblastoma.
Journal: Current pharmaceutical design
Published: August 15, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026